Peanut allergy is an IgE-mediated food allergy that can trigger rapid and potentially life-threatening allergic reactions, including anaphylaxis, after peanut exposure.
Slow up-dosing peanut OIT enabled 82% of toddlers to tolerate 3.5 peanuts after treatment. Low-dose OIT was safe in preschoolers with single or multiple food allergies. Allergist guidance on anxiety was linked to reduced caregiver worry.
Pfizer's tilrekimig met its primary endpoint in a mid-stage eczema trial and will advance to late-stage testing. Separately, oral remibrutinib demonstrated rapid efficacy in treating peanut allergy in a phase II study.
Novartis reported positive Phase III RemIND trial results showing remibrutinib achieved complete response in three types of chronic inducible urticaria. The company has submitted a supplemental New Drug Application to the FDA for symptomatic dermographism.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07580898 |
Safety of MOON101 for the Treatment of Peanut Allergy |
NOT_YET_RECRUITING | PHASE1 |
| NCT07439406 |
Comparing Standard and Autoclaved Peanut Oral Immunotherapy in People With Peanut Allergy |
NOT_YET_RECRUITING | PHASE2 |
| NCT07349212 |
UKK-0018 as an Immunotherapeutic for Treatment of Peanut Allergies |
RECRUITING | PHASE1/PHASE2 |
| NCT07117669 |
Study of ENP-501 in Peanut-Allergic and Non-Allergic Participants |
RECRUITING | PHASE1/PHASE2 |
| NCT07015996 |
Efficacy of Tezepelumab in Peanut Oral Immunotherapy |
NOT_YET_RECRUITING | PHASE2 |
| NCT07003919 |
Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers) |
RECRUITING | PHASE3 |
| NCT06331728 |
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IGNX001 |
COMPLETED | PHASE1 |
| NCT06297083 |
Analysing HIgh Dose Probiotic Peanut Oral Immunotherapy (PPOIT) and High Dose Peanut Oral Immunotherapy (OIT) Versus LOw Dose Peanut OIT for Peanut Allergy |
WITHDRAWN | PHASE2 |
| NCT06256146 |
Investigating Modified Protocols of Oral Immunotherapy to Validate Efficacy and Safety |
RECRUITING | NA |
| NCT05695261 |
Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients |
RECRUITING | PHASE2 |
